Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity

Clinical Cancer Research

Volumn 12, Issue 19, 2006, Pages 5834-5840

  Chen, Xin Yuan ^a   Zhang, Wei ^a   Zhang, Wang ^a   Wu, Sheng ^a   Bi, Feng ^a   Su, Yi Jing ^a   Tan, Xiang Yang ^a   Liu, Jian Ning ^a   Zhang, Jing ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CANCER ANTIBODY; CANCER VACCINE; PHOSPHATE BUFFERED SALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; HUMORAL IMMUNITY; LEWIS CARCINOMA; LIFESPAN; METASTASIS; MOUSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UMBILICAL VEIN; VACCINATION;

ANIMALS; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, LEWIS LUNG; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNITY, CELLULAR; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL RATE; T-LYMPHOCYTES; UMBILICAL VEINS; VACCINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33750318651     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1105     Document Type: Article

References (33)

1. Fishbein GE. Immunotherapy of lung cancer. Semin Oncol 1993;20:351-8.
2. Al-Moundhri M, O'Brien M, Souberbielle BE. Immunotherapy in lung cancer. Br J Cancer 1998;78:282-8.
3. Foon KA. Immunotherapy for colorectal cancer. Curr Oncol Rep 2001;3:116-26.
4. Zeh HJ, Stavely-O'Carroll K, Choti MA. Vaccines for colorectal. Trends Mol Med 2001;7:307-13.
5. Boon T, Cerottini JC, Van den Eynde B. Tumor antigens recognized by T lymphoctes. Annu Rev Immunol 1994;12:337-65.
6. Barth N, West W, Oldham R. A phase II trial of adoptive immunotherapy and sequential chemotherapy with cisplatin, VP-16 in advanced non-small cell lung cancer. Proc ASCO 1990;9:235-43.
7. Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998;160:3081-5.
8. Celluzzi CM, Mayordomo JI, Storkus WJ. Peptide-pulsed dendritic cells induce antigen-specific, cytotoxic T lymphocyte-mediated protective immunity. J Exp Med 1996;183:519-27.
9. Shin MS, Kim HS, Lee SH, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61:4942-6.
10. Folkman J. Addressing tumor blood vessels. Nat Biotechnol 1997;15:510.
11. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
12. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
13. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:167-8.
14. Tozer GM, Bicknell R. Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol 2004;14:222-32.
15. Modzelewski RA, Davies P, Watkins SC, Auerbach R, Chang MJ, Johnson CS. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 1994;54:336-9.
16. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
17. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001;61:6649-55.
18. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001;91:749-56.
19. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994;179:1205-14.
20. Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 2005;106:2026-32.
21. Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000;6:1160-6.
22. Okaji Y, Tsuno NH, Kitayama J, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004;95:85-90.
23. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphology and immunologic criteria. J Clin Invest 1973;52:2745-56.
24. Werner C, Klouda PT, Correa MC, Vassalli P, Jeannet M. Isolation of B and T lymphocytes by nylon fiber columns. Tissue Antigens 1977;9:227-9.
25. Lowry R, Goguen J, Carpenter CB, Strom TB, Garovoy MR. Improved B cell typing for HLA-DR using nylon wool column enriched B lymphocyte preparations. Tissue Antigens 1979;14.325-30.
26. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
27. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369-75.
28. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 2003;21:223-31
29. Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-72.
30. Yoshimoto A, Kasahara K, Nishio M, et al. Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. Jpn J Clin Oncol 2005;35:233-8.
31. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70.
32. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
33. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998;95:10820-5.